圣达生物(603079) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for the first half of 2024 to be between 18 million and 22 million yuan, indicating a turnaround from a loss in the same period last year [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between 4.6 million and 5.8 million yuan for the first half of 2024 [12]. - The company reported a net loss of 6.33 million yuan attributable to shareholders in the previous period [7]. - The earnings per share for the previous period was reported at -0.04 yuan per share [14]. - The company aims to achieve a turnaround in net profit for the first half of 2024 compared to the previous year [17]. Business Strategy - The company has optimized its product sales structure compared to the same period last year, focusing on high-value products such as pharmaceutical-grade vitamins and clean label products, which have seen revenue growth [3]. - The company emphasizes refined management and technological improvements, achieving cost reduction and efficiency enhancement [3]. Earnings Forecast - The earnings forecast has not been audited by a registered accountant, and the figures are preliminary estimates [15]. - The company has no significant uncertainties that could impact the earnings forecast [8]. - The official financial data will be disclosed in the formal report for the first half of 2024, and investors are advised to be aware of investment risks [15].